Transplanting solid organs from HBsAg negative donors positive for antibody to hepatitis B core antigen: The implications

International Journal of Artificial Organs

Volumn 26, Issue 11, 2003, Pages 972-983

  Fabrizi, Fabrizio ^a,b   Bunnapradist, S ^b   Lunghi, G ^c   Villa, M ^a   Martin, P ^b  

^a Milan Policlinico   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B;

BIOMATERIALS;

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN A; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; LYMPHOCYTE ANTIBODY; PREDNISOLONE; STEROID; TACROLIMUS;

ANTIBODY DETECTION; CADAVER DONOR; CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOW DRUG DOSE; NONHUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; PATIENT SELECTION; POLYMERASE CHAIN REACTION; RECIPIENT; REVIEW; SEROLOGY; VACCINATION; VIRUS REACTIVATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 1242319572     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880302601102     Document Type: Review

References (91)

1. Rosenthal JT. Expanded criteria for cadaver organ donation in renal transplantation. Urol Clin North Am 1994; 21: 283-7.
2. Terasaki PI, Cho YW, Cecka JM. Strategy for eliminating the kidney shortage. Clin Transplant 1997; 265-7.
3. Cho YW. Expanded criteria donors. Clin Transplant 1998; 421-36.
4. Cho YW, Terasaki PI, Cecka JM, Gjertson DW. Transplantation of kidneys from donors whose hearts have stopped beating. N Engl J Med 1998; 338: 221-5.
5. Gonzalez-Peralta RP, Andres JM, Tung FY, Fang JW, Brunson ME, Davis GL, Lau YN. Transplantation of a hepatitis B surface-antigen positive donor liver into a hepatitis B virus negative recipient. Transplantation 1994; 58: 114-6.
6. Hoft RH, Pflugfelder SC, Forster RK, Ullman S, Polack FM, Schiff ER. Clinical evidence for hepatitis B transmission resulting from corneal transplantation. Cornea 1997; 16: 132-7.
7. Chan MK, Chang WK. Renal transplantation from HBsAg positive donors to HBsAg negative recipients (letter). Br Med J 1988; 297: 522-3.
8. Landreneau MD, DeVault GA, Rohr MS, Kilpatrick JS, King JW, Rhynes VK, Gonzalez E, McDonald JC. Transmission of hepatitis B by renal transplantation despite active immunization with hepatitis B vaccine. Clin Transplant 1988; 2: 265-9.
9. Wolf JL, Perkins HA, Schreeder MT, Vincenti F. The transplanted kidney as a source of hepatitis B infection. Ann Intern Med 1979; 91: 412-4.
10. Lutwick LI, Sywassink JM, Corry RJ, Shorey JW. The transmission of hepatitis B by renal transplantation. Clin Nephrol 1983; 19: 317-9.
11. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-3.
12. Hiesse C, Buffet C, Neyrat N, Ricu P, Charpentier B, Etienne JP, Fries D. Impact of HBs antigenemia on long-term patient survival and causes of death after renal transplantation. Clin Transplant 1992; 46: 461-7.
13. Pfaff WW, Blanton JW. Hepatitis antigenemia and survival after renal transplantation. Clin Transplant 1997; 11: 476-9.
14. Breitenfeldt MK, Rasenack J, Berthold H, Olschewski M, Schroff J, Strey C, Grotz WH. Impact of hepatitis B and C on graft loss and mortality of patients after kidney transplantation. Clin Transplant 2002; 16: 130-6.
15. Lee WC, Shu KH, Cheng CH, Wu MJ, Chen CH, Lian JD. Long-term impact of hepatitis B, C virus infection on renal transplantation. Am J Nephrol 2001; 21: 300-6.
16. Kairaritis LK, Gottlieb T, George CR. Fatal hepatitis B virus infection with fibrosing cholestatic hepatitis following renal transplantation. Nephrol Dial Transplant 1998; 13: 1571-3.
17. Hanson CA, Sutherland DE, Snover DC. Fulminant hepatic failure in an HBsAg carrier renal transplant patient following cessation of immunosuppressive therapy. Transplantation 1985; 39: 311-2.
18. Fabrizi F, Martin P. Hepatitis in kidney transplantation. In: Danovitch G, ed. Handbook of kidney transplantation. Philadelphia: Lippincott Williams & Wilkins, 2001; pp. 263-71.
19. Kasiske B, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, Rush DN, Vazquez MA, Weir MR. The evaluation of renal transplant candidates: clinical practice guidelines. Am J Transplant 2001; 2 (suppl 1): S5-95.
20. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
21. Chung RT, Fang S, Delmonico FL. Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor. Am J Transplant 2001; 1: 185-91.
22. Levy P, Marcellin P, Martinot-Peignoux M, Degott C, Nataf J, Benhamou JP. Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology 1990; 12: 570-4.
23. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, Costa J. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447-9.
24. Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-8.
25. Brechot C, Degos F, Lugassy C, Thiers V, Zafrani S, Franco D, Bismuth H, Trepo C, Benhamou JP, Wands J. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med 1985; 312: 270-6.
26. Kuhns M, McNamara A, Mason A, Campbell C, Perrillo R. Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology 1992; 103: 1649-56.
27. Fong TL, Di Bisceglie AM, Gerber MA, Waggoner JG, Hoofnagle JH. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993; 18: 1313-8.
28. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994; 93: 230-9.
29. Rehermann B, Lau D, Hoofnagle JH, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-8.
30. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, Rehermann B, Fiaccadori F, Ferrari C. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 1185-94.
31. Cabrerizo M, Bartolomè J, De Sequera P, Caramelo C, Carreno V. Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis and staff. J Am Soc Nephrol 1997; 8: 1443-7.
32. Conjeevaram HS, Lok ASF. Occult hepatitis B virus infection: a hidden menace? Hepatology 2001; 34: 204-6.
33. Noborg U, Gusdal A, Horal P, Lindh M. Levels of viraemia in subjects with serological markers of past or chronic hepatitis B virus infection. Scand J Infect Dis 2000; 32: 249-52.
34. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely "occult"? Hepatology 2001; 3: 194-203.
35. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.
36. Hoofnagle JH, Seeff LB, Bales ZB, Zimmermann HJ. Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen. N Engl J Med 1978; 298: 1379-83.
37. Thiers V, Kremsdorf D, Schellekens H, Goudeau A, Sinski J, Nakaijma E, Mack D, Driss F, Wands J, Tiollais P, Brechot C. Transmission of hepatitis B from hepatitis B seronegative subjects. Lancet 1988; i: 1273-6.
38. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437-55.
39. Anderson NAB, Raafat A, Shwe KE, Barbara J, Contreras M, Fraser ID, Gunson HH, Martlew V, Mijovic V, Goldie DJ. UK multicentre study on blood donors for surrogate markers of non-A non-B hepatitis. Part 1: Alanine transferase and anti-HBc testing. Transfus Med 1992; 2: 301-5.
40. Dusheiko G, Song E, Bowyer S, Whitcutt M, Maier G, Meyers A, Kew MC. Natural history of hepatitis B virus infection in renal transplant recipients- a fifteen-year follow-up. Hepatology 1983; 3: 330-6.
41. Nagington J, Cossart YE, Cohen BJ. Reactivation of hepatitis B after transplantation operations. Lancet 1977; i: 558-60.
42. Waters J, Pignatelli M, Galpin S, Ishikara K, Thomas HC. Virus-neutralizing antibodies to hepatitis B virus: the nature of an immunogenic epitope on the S gene peptide. J Gen Virol 1986; 67: 2467-73.
43. Treichel U, Meyer zum Buschenfelde KH, Stockert RJ, Poralla T, Gerken G. The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers. J Gen Virol 1994; 75: 3021-9.
44. Grotz W, Rasenack J, Benzing T, Berthold H, Peters T, Walter E, Schollmeyer P, Rump LC. Occurrence and management of hepatitis B virus reactivation following kidney transplantation. Clin Nephrol 1998; 49: 385-8.
45. Marcellin P, Giostra E, Martinot-Peignoux M, Loriot MA, Jaegle ML, Wolf P, Degott C, Degos F, Benhamou JP. Redevelopment of hepatitis B surface antigen after renal transplantation. Gastroenterology 1991; 100: 1432-4.
46. Blanpain C, Knoop C, Delforge ML, Antoine M, Peny MO, Liesnard C, Vereerstreaeten P, Cogan E, Adler M, Abramowicz D. Reactivation of hepatitis B after transplantation in patients with pre-existing anti-hepatitis B surface antigen antibodies. Transplantation 1998; 66: 883-6.
47. Kidd-Liungren K, Simonsen O. Reappearance of hepatitis B 10 years after kidney transplantation (letter). N Engl J Med 1999; 341: 127-8.
48. Chen PM, Fan S, Liu JH, Chiou TJ, Hsieh SR, Liu RS, Tzeng CH. Reactivation of hepatitis B virus in two chronic GVHD patients after transplant. Int J Hematol 1993; 58: 183-8.
49. Locasciulli A, Testa M, Valsecchi MG, Vecchi L, Longoni D, Sparano P, Rovelli A, Uderzo C, Masera G, Alberti A. Morbidity and mortality due to liver disease in children undergoing allogeneic bone marrow transplantation: A 10-year prospective study. Blood 1997; 90: 3799-805.
50. Grumayer ER, Panzer S, Ferneci P, Gadner H. Recurrence of hepatitis B in children with serologic evidence of past hepatitis B virus infection undergoing antileukemic chemotherapy. J Hepatol 1989; 8: 232-5.
51. Lazizi Y, Grangeol-Keros L, Delfraissy JF, Boue F, Dubreuil P, Badur S, Pillot J. Reappearance of hepatitis B virus in immune patients infected with the human immunodeficiency virus type I. J Infect Dis 1988; 158: 666-7.
52. Vento S, Di Perri G, Luzzati R, Cruciani L, Garofano T, Mengoli C, Concia E, Bassetti D. Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. (letter) Lancet 1989; 2: 332.
53. Bouslama K, Knani L, Cabane J, Picard O, Lebas J, Poupon R, Imbert JC. Reactivation of B hepatitis in an anti-HBs positive patient in HIV co-infection. An Med Interna 1991; 142: 63-4.
54. Maguire D, Heaton ND, Smith HM. Failure of reactivation of hepatitis B after liver transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients. Transplantation 2002; 72: 481-2.
55. Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Gallorini A, Ruol A, Alberti A. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology 1994; 105: 1529-33.
56. Roche B, Samuel D, Gigou M, Feray C, Virot V, Schmets L, David MF, Arulnaden JL, Bismuth A, Reynes M, Bismuth H. De novo and apparent de novo hepatitis B virus infection after liver transplantation. J Hepatol 1997; 26: 517-26.
57. Farza H, Salmon AM, Hadchoeul M, Moreau JL, Babinet C, Tiollais P, Pourcel C. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice. Proc Natl Acad Sci USA 1987; 84: 1187-91.
58. Tur Kaspa R, Burk RD, Shaul Y, Moore DD, Shafrotz DA. Hepatitis B virus DNA contains a glucocorticoid responsive element. Proc Natl Acad Sci USA 1986; 83: 1627-31.
59. McMillan JS, Shaw T, Angus PW, Locarnini SA. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 1995; 22: 36-43.
60. Cote PJ, Tennat BC, Baldwin B, Korba BE, Gerin JL. Modulation of WHV infection and disease with cyclosporine A and dexamethasone. International Symposium on Viral Hepatitis and Liver Diseases, Houston, 1990.
61. Aldersley MA, Eglin RE, O'Grady JG. Liver transplantation and de novo hepatitis B infection (letter). Lancet 1994; 343: 677.
62. Chazouilleres O, Mamish D, Kim M, Carey K, Ferrell L, Roberts JP, Ascher NL, Wright TL. 'Occult' hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994; 343: 142-6.
63. Wachs M, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, Melzer HS, Roberts JP, Tomlanovich SJ, Vincenti F, Stock P. The risk of transmission of hepatitis B from HBsAg (-), HBcAb (-), HBIgM (-) organ donors. Transplantation 1995; 59: 230-4.
64. Lowell JA, Howard TK, White HM, Shenoy S, Huettner PC, Brennan DC, Peters MG. Serological evidence of past hepatitis B infection in liver donor and hepatitis B infection in liver allografts. Lancet 1995; 345: 1084-5.
65. Radomski JS, Moritz MJ, Armenti VT, Munoz SJ. Hepatitis B transmission from a liver donor who tested negative for hepatitis B surface antigen and positive for hepatitis B core antibody. Liver Transpl Surg 1996; 2: 130-1.
66. Douglas DD, Rakela J, Wright TL, Krom RAF, Wiesner RH. The clinical course of transplantation associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997; 3: 105-11.
67. Uemoto S, Sugiyama K, Marusawa H, Inomata Y, Asonuma K, Egawa H, Kiuchi T, Miyake Y, Tanaka K, Chiba T. Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 1998; 65: 494-9.
68. Dickson RC, Everhart JE, Lake JR, Wei Y, Seaberg EC, Wiesner RH, Zetterman RK, Pruett TL, Ishitani MB, Hoofnagle JH, and The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 1997; 113: 1668-74.
69. Todo S, Demetris AJ, van Thiel DH, Fung JJ, Iwaki Y, Sysyn G, Ming W, Trager J, Starzl TE. Evolution of hepatitis B virus liver disease after hepatic replacement. Am J Pathol 1990; 137: 667-76.
70. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJM, Williams R. Hepatic histologic findings after transplantation for chronic hepatitis B virus infection; including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150-7.
71. Lucey MR, Graham DM, Martin P, Di Bisceglie A, Rosenthal S, Waggoner HG, Merion RM, Campbell DA, Nostrant TT, Appelman HD. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992; 33: 1390-6.
72. Konig V, Hopf U, Neuhaus P, Bauditz A, Schmidt CA, Blumhardt G, Bechstein WO, Neuhaus R, Lobeck H. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994; 58: 553-9.
73. Dodson SF, Issa S, Araya V, Gayowski T, Pinna A, Eghtesad B, Iwatsuki S, Montalvo E, Rakela J, Fung JJ. Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 1997; 64: 1582-4.
74. Chen YS, Wang CC, de Villa VH, Wang SH, Cheng YF, Huang TL, Iawan B, Chiu KW, Chen CL. Prevention of de novo hepatitis B virus infection in living donor liver transplantation using hepatitis B core antibody positive donors. Clin Transplant 2002; 16: 405-9.
75. Dodson SF, Bonham CA, Geller DA, Cacciarelli TV, Rakela J, Fung JJ. Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 1999; 68: 1058-61.
76. Joya-Vazquez PP, Dodson FS, Dvorchik I, Gray E, Chesky A, Demetris AJ, Shakil O, Fung JJ, Vargas HE. Impact of antihepatitis B core-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation 2002; 73: 1598-602.
77. Satterthwaite R, Ozgu I, Shibdan H, Aswad S, Sunga V, Zapanta R, Asai P, Bogaard T, Khetan U, Mendez RG, Mendez R. Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors. Transplantation 1997; 64: 432-5.
78. Madayag RM, Johnson LB, Bartlett ST, Schweitzer EJ, Constantine NT, McCarter RJ, Kuo PC, Keay S, Oldach DW. Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 1997; 64: 1781-6.
79. Krieger NR, Vial CM, Millan MT, Imperial J, Dafoe DC, Scandling JD. Revisiting the use of hepatitis B core antibody-positive donor kidneys. Transplant Proc 2001; 33: 1535-6.
80. Kadian M, Hawkins K, Schwartz H, Miller C. Use of hepatitis B core antibody-positive multi-organ donors. J Transplant Coord 1994; 4: 57-60.
81. Fong TL, Bunnapradist S, Jordan SC, Cho YW. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: analysis of United Network of Organ Sharing database between 1994 and 1999. Transplantation 2002; 73: 85-9.
82. Cirocco R, Zucker K, Contreras N, Olson L, Cravero J, Markou M, Babischkin S, Fernandez E, Burke GW, Esquenazi V, Tzakis A, Miller J. The presence of hepatitis B core antibody does not preclude kidney donation. Lack of viral DNA in the serum and biopsies of core antibody positive donors and clinical follow-up (letter). Transplantation 1997; 63: 1702-4.
83. Turner DP, Zuckerman M, Alexander GJM, Waite J, Wreghitt T. Risk of inappropriate exclusion of organ donors by introduction of hepatitis B core antibody testing. Transplantation 1997; 63: 775-8.
84. Kroes ACM, Quint WGV, Heijtink RA. Significance of isolated hepatitis B core antibodies detected by enzyme immunoassay in a high risk population. J Med Virol 1991; 35: 96-9.
85. Hughes W, Barr A, Dow BC, Follett EAC, Barbara JAJ. A multicentre assessment of the specificity of ten anti-HBc screening tests. Transfus Med 1995; 5: 225-9.
86. Delmonico FL, Snydman DR. Organ donor screening for infectious diseases. Transplantation 1998; 65: 603-10.
87. Terrault N, Zhou S, Combs C, Hahn JA, Lake JR, Roberts JP, Ascher NL, Wright TL. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327-33.
88. Mutimer D, Dusheiko G, Barrett C, Grellier L, Ahmed M, Anschuetz G, Burroughs A, Hubscher S, Dhillon AP, Rolles K, Elias E. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 2000; 70: 809-15.
89. Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H, Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NG, Imagawa DK, Holt C, Goldstein LI, Stribling R, Busuttil RW. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-9.
90. Han SF, Ofman J, Holt C, King K, Kunder G, Chen P, Dawson S, Goldstein L, Yersiz H, Farmer DG, Ghobrial RM, Busuttil RW, Martin P. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl 2000; 6: 741-8.
91. Douglas DRJ, Mamish D, Wright T, Krom R, Wiesner R. Transmission of hepatitis B virus infection from orthotopic donor livers. (abstract). Hepatology 1992; 16: 49 A.